Zealand Pharma A/S at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: James Gordon - JPMorgan - Analyst : Thank you very much. We've now got some time for questions. Is this on? Can you hear me now? Testing. Well, there's also other microphone. Does that -- I think with that, is there any in the audience have a question they'd like to ask? Otherwise, I've got one line up. Maybe I'll start with a question on amylin. It's been quite a busy couple of weeks for amylin. We've had another company announcing was the CagriSema data, so another amylin therapy. The market's reaction wasn't that positive. What do you think of the data? And what does it mean for amylin as a class? Does this change how we should think about your amylin, petre?

Question: James Gordon - JPMorgan - Analyst : Thank you. Question to the -- pass with the hand up there. If you wait for the microphone one second, just so everyone could hear you. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 10:15PM, ZELA.CO - Zealand Pharma A/S at JPMorgan Healthcare Conference Unidentified Participant Thank you. I have two questions. One, you just mentioned, people have said, in general, females, just quick, is more sensitive to GLP-1-related drugs. Male -- where did you get this conclusion? This is my question.

Question: James Gordon - JPMorgan - Analyst : I think it was the question about the weight loss by gender, the data to support -- I think it's the women lose weight more quickly versus men was the question. Unidentified Participant Correct.

Question: James Gordon - JPMorgan - Analyst : Could you hold your microphone like this? Unidentified Participant Yeah. Thank you very much. You just joke about when people are given with GLP-1 drugs, they couldn't suffer a restaurant. They couldn't go there, right? I totally agree with you. The preservation of the present sensations is very important for patients. But have you looked into the -- how much appetite being left when people are receiving your drugs?

Question: James Gordon - JPMorgan - Analyst : A question from the lady in front, please? Unidentified Participant Thank you. A quick question. You've cited that you think the reason why the cagrilintide arm didn't do quite as well as what you expect for petre is because this is under dosed, if I understood correctly. But there also appears to be a suggestion that, as you go from, I think, the data initially was at about 36 weeks to 68 weeks, there wasn't a material change in the weight loss profile as you would normally see with the GLP-1. How do you think -- because I'm thinking about your target profile. And on the one hand, you adjust for having more females and I get that, they're much more compliant. On the other hand, you're going to have a much higher dose. But just what about the improving weight profile over time?

Question: James Gordon - JPMorgan - Analyst : Could I ask in terms of partnering. So if you could remind us where we are with petre partnering? What still needs to happen? Do we need any more clinical data from your point of view? Or is there any more Zealand data or any other competitor readouts? Or is the path now clear?

Question: James Gordon - JPMorgan - Analyst : Is there a question over there, please? I see one, so that one and then that one? Unidentified Participant Could you comment on the opportunity for an oral drug here just in terms of how much share that could take for the market and for you as well?

Question: James Gordon - JPMorgan - Analyst : Great. I think given the time, we better wrap up there. But thank you very much.